Interaction between Spike Protein of SARS-CoV-2 and Human Virus Receptor ACE2 Using Two-Color Fluorescence Cross-Correlation Spectroscopy

被引:3
作者
Fujimoto, Ai [1 ]
Lyu, Yidan [1 ]
Kinjo, Masataka [1 ]
Kitamura, Akira [1 ]
机构
[1] Hokkaido Univ, Fac Adv Life Sci, Lab Mol Cell Dynam, Sapporo 0010021, Japan
来源
APPLIED SCIENCES-BASEL | 2021年 / 11卷 / 22期
关键词
COVID-19; spike protein; ACE2; fluorescence cross-correlation spectroscopy; coronavirus;
D O I
10.3390/app112210697
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is initiated by the interaction between a receptor protein, angiotensin-converting enzyme type 2 (ACE2) on the cell surface, and the viral spike (S) protein. This interaction is similar to the mechanism in SARS-CoV, a close relative of SARS-CoV-2, which was identified in 2003. Drugs and antibodies that inhibit the interaction between ACE2 and S proteins could be key therapeutic methods for preventing viral infection and replication in COVID-19. Here, we demonstrate the interaction between human ACE2 and a fragment of the S protein (S1 subunit) derived from SARS-CoV-2 and SARS-CoV using two-color fluorescence cross-correlation spectroscopy (FCCS), which can detect the interaction of fluorescently labeled proteins. The S1 subunit of SARS-CoV-2 interacted in solution with soluble ACE2, which lacks a transmembrane region, more strongly than that of SARS-CoV. Furthermore, one-to-one stoichiometry of the two proteins during the interaction was indicated. Thus, we propose that this FCCS-based interaction detection system can be used to analyze the interaction strengths of various mutants of the S1 subunit that have evolved during the worldwide pandemic, and also offers the opportunity to screen and evaluate the performance of drugs and antibodies that inhibit the interaction.
引用
收藏
页数:10
相关论文
共 31 条
[1]   Fluorescence cross-correlation spectroscopy in living cells [J].
Bacia, K ;
Kim, SA ;
Schwille, P .
NATURE METHODS, 2006, 3 (02) :83-89
[2]   Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2 [J].
Baral, Pravas Kumar ;
Yin, Jiang ;
James, Michael N. G. .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2021, 186 :490-500
[3]   Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites [J].
Belouzard, Sandrine ;
Chu, Victor C. ;
Whittaker, Gary R. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (14) :5871-5876
[4]   Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion [J].
Benton, Donald J. ;
Wrobel, Antoni G. ;
Xu, Pengqi ;
Roustan, Chloe ;
Martin, Stephen R. ;
Rosenthal, Peter B. ;
Skehel, John J. ;
Gamblin, Steven J. .
NATURE, 2020, 588 (7837) :327-330
[5]   A palette of fluorescent proteins optimized for diverse cellular environments [J].
Costantini, Lindsey M. ;
Baloban, Mikhail ;
Markwardt, Michele L. ;
Rizzo, Mark ;
Guo, Feng ;
Verkhusha, Vladislav V. ;
Snapp, Erik L. .
NATURE COMMUNICATIONS, 2015, 6
[6]   A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 [J].
Donoghue, M ;
Hsieh, F ;
Baronas, E ;
Godbout, K ;
Gosselin, M ;
Stagliano, N ;
Donovan, M ;
Woolf, B ;
Robison, K ;
Jeyaseelan, R ;
Breitbart, RE ;
Acton, S .
CIRCULATION RESEARCH, 2000, 87 (05) :E1-E9
[7]   Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data [J].
Haas, Eric J. ;
Angulo, Frederick J. ;
McLaughlin, John M. ;
Anis, Emilia ;
Singer, Shepherd R. ;
Khan, Farid ;
Brooks, Nati ;
Smaja, Meir ;
Mircus, Gabriel ;
Pan, Kaijie ;
Southern, Jo ;
Swerdlow, David L. ;
Jodar, Luis ;
Levy, Yeheskel ;
Alroy-Preis, Sharon .
LANCET, 2021, 397 (10287) :1819-1829
[8]  
Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI [10.1038/s41594-020-0469-6, 10.1038/s41594-020-00527-9]
[9]   Neutralizing Antibody Therapeutics for COVID-19 [J].
Hurt, Aeron C. ;
Wheatley, Adam K. .
VIRUSES-BASEL, 2021, 13 (04)
[10]   Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay [J].
Jang, Woo Dae ;
Jeon, Sangeun ;
Kim, Seungtaek ;
Lee, Sang Yup .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (30)